Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Editas Medicine, Inc.

< Previous 1 2 Next >
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces First Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers BMY EDIT
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback